Claims for Patent: 12,708,626

« Back to Dashboard

Summary for Patent: 12,708,626

Title:	Liquid oral formulations for tadalafil
Abstract:	The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.
Inventor(s):	Jinal Pandya, Sandip P. Mehta, Manish Umrethia, Jayanta Kumar Mandal, Hiren Pansuriya
Assignee:	Liqmeds Worldwide Ltd
Application Number:	US18/624,230
Patent Claims:	1. A liquid oral pharmaceutical composition comprising: about 4 mg/mL tadalafil or a pharmaceutically acceptable salt thereof, wherein the tadalafil comprises particulate tadalafil; a pharmaceutically acceptable excipient; and a vehicle comprising water; wherein the pharmaceutical composition has a pH of from about 4 to about 8; and wherein the composition exhibits a dissolution rate of at least about 90% in 10 minutes when measured in 0.5% sodium lauryl sulfate. 2. The liquid oral pharmaceutical composition of claim 1, wherein the dissolution rate is at least about 94% in 10 minutes when measured in 0.5% sodium lauryl sulfate. 3. The liquid oral pharmaceutical composition of claim 1, wherein the tadalafil comprises particulate tadalafil having a d90 particulate size of from about 5 microns to about 50 microns. 4. The liquid oral pharmaceutical composition of claim 1, wherein the tadalafil comprises particulate tadalafil having a d90 particulate size of from about 5 microns to about 20 microns. 5. The liquid oral pharmaceutical composition of claim 1, wherein the tadalafil comprises particulate tadalafil having a d90 particulate size of about 8 microns. 6. The liquid oral pharmaceutical composition of claim 5, wherein the dissolution rate is at least about 94% in 10 minutes in 0.5% sodium lauryl sulfate. 7. The liquid oral pharmaceutical composition of claim 1, wherein the tadalafil comprises particulate tadalafil having a d90 particulate size of from about 25 microns to about 200 microns. 8. The liquid oral pharmaceutical composition of claim 1, wherein the liquid oral pharmaceutical composition has a pH of about 5. 9. The liquid oral pharmaceutical composition of claim 6, wherein the liquid oral pharmaceutical composition has a pH of about 5. 10. The liquid oral pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable excipient comprises a wetting agent. 11. The liquid oral pharmaceutical composition of claim 10, wherein the wetting agent is selected from the group consisting of glycerin, propylene glycol, polyethylene glycol, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, sodium lauryl sulfate, and combinations thereof. 12. The liquid oral pharmaceutical composition of claim 10, wherein the wetting agent is glycerin present in an amount of from about 200 mg/mL to about 800 mg/mL. 13. The liquid oral pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable excipient comprises a viscosity modifying agent. 14. The liquid oral pharmaceutical composition of claim 13, wherein the viscosity modifying agent comprises xanthan gum, hydroxypropylmethyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, microcrystalline cellulose, or a combination thereof. 15. The liquid oral pharmaceutical composition of claim 13, wherein the viscosity modifying agent comprises xanthan gum in an amount of from about 1 mg/mL to about 6 mg/mL. 16. The liquid oral pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable excipient comprises a buffering agent. 17. The liquid oral pharmaceutical composition of claim 16, wherein the buffering agent comprises citric acid and tri-sodium citrate. 18. The liquid oral pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable excipient comprises at least one of: (i) a preservative; (ii) a sweetener; or (iii) a flavorant. 19. The liquid oral pharmaceutical composition of claim 18, wherein the preservative comprises sodium benzoate, the sweetener comprises sucralose, and the flavorant comprises peppermint flavor. 20. The liquid oral pharmaceutical composition of claim 1, wherein the composition retains at least about 95% of labeled tadalafil concentration after storage for at least 6 months at 25° C. and 60% relative humidity. 21. The liquid oral pharmaceutical composition of claim 1, wherein the composition contains no more than about 2% total tadalafil-related impurities after storage for at least 6 months at 25° C. and 60% relative humidity. 22. A method for treating pulmonary arterial hypertension, which comprises administering to a human patient in need thereof a therapeutically effective amount of the liquid oral pharmaceutical composition of claim 1. 23. A method for treating erectile dysfunction, which comprises administering to a human patient in need thereof a therapeutically effective amount of the liquid oral pharmaceutical composition of claim 1. 24. A method for treating benign prostatic hyperplasia, which comprises administering to a human patient in need thereof a therapeutically effective amount of the liquid oral pharmaceutical composition of claim 1.